Structure Therapeutics Stock Climbs 3.92% on New Obesity Drug Trial

source:

[1] Structure Therapeutics Announces Initiation of Phase 1 Clinical Study of Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity (https://finance.yahoo.com/news/structure-ther ...)

Structure Therapeutics Stock Climbs 3.92% on New Obesity Drug Trial

Related News

Corcept Therapeutics Plummets 48%, Marking Worst Day in 11 Years

NIO Plunges 5% as Chinese EV Stocks Lead Market Decline

Shandong Zhanggu Faces CSRC Probe Over Financial Disclosures